Lindy Biosciences

Lindy Biosciences, founded in 2021 and based in Cambridge, MA, is a private, pre-revenue platform company focused on transforming the delivery of biologic drugs. Its core innovation is the Microglassification™ technology, a dehydration process that enables the formulation of highly concentrated protein therapeutics suitable for subcutaneous injection, thereby facilitating patient self-administration. The company is actively seeking industry partnerships to apply its platform to partners' drug candidates, positioning itself as a technology enabler rather than a drug developer. Led by a team with expertise in materials science, pharmaceuticals, and business development, Lindy aims to address the significant market need for more convenient administration of chronic disease therapies.

Microglassification™, a dehydration technology enabling highly concentrated protein suspensions for subcutaneous injection.

Lindy competes in the drug delivery formulation space with other private and public companies developing technologies for high-concentration protein formulations, alternative subcutaneous delivery methods (e.g., autoinjectors, pumps), and novel excipients. Its success depends on demonstrating superior compatibility, concentration capability, and ease of integration for partners.